In 2008, the six tumor types covered in this report are forecast to account for over 1.2m new cases of cancer. Collectively, the 36 different drugs in Phase III development for the six tumor types are forecast to achieve $7,049m in sales by 2017. This constitutes a significant proportion of the oncology market, thus representing ample commercial opportunities for drug developers.

Scope

Examination of the solid cancer pipeline with in-depth clinical and commercial profiles of Phase III candidates for six tumor types
Seven major pharmaceutical market sales forecasts for Phase III pipeline products through to 2017 with product-specific assumptions
Segmentation and analysis of the current solid tumor pipeline by developmental phase, drug class and indication for six tumor types
Insight and analysis of market potential including commercial opportunity, epidemiology, commonalities across cancers and discussion of unmet needs

Highlights

Avastin (bevacizumab; Genentech/Roche) has shown the greatest potential in the ovarian cancer pipeline to date, with encouraging response rates in heavily pretreated patients, alongside the commercially favorable backing of Genentech and Roche, who have considerable experience in the oncology market.

Abiraterone (CB-7630; Cougar Biotechnology/BTG) shows the greatest potential in the prostate cancer pipeline. Abiraterone shows real promise in providing an effective therapy in the second-line or higher setting among patients where all lines of antihormonal therapy and Taxotere (docetaxel; Sanofi-Aventis) have failed.

In the RCC pipeline, Afinitor (everolimus; Novartis) shows the most promise, by providing a treatment option for tyrosine kinase inhibitor-refractory patients, who currently face a lack of viable therapies. Afinitor is the first drug to show a Phase III clinical benefit in this patient population, which could have a great impact on treatment.

Reasons to Purchase

Identify key drugs and companies within the oncology pipeline based on sales forecasts to 2017 and Datamonitor drug assessment
Characterize unmet need and poorly served markets within oncology and assess the potential for pipeline products to provide satisfaction
Assess the shifting oncology market dynamic and how future treatment of solid tumors will incorporate pipeline products

ABOUT DATAMONITOR HEALTHCARE
- About the Oncology pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY
- Scope of the analysis
- Datamonitor insight into the cancer market
- Related reports
- Upcoming reports
CHAPTER 2 PIPELINE OVERVIEW AND DYNAMICS
- Pipeline overview
  - Late-phase pipeline
  - Pipeline by indication
    - Breast cancer and prostate cancer will always remain popular R&D targets, however, the niche indications are increasing in popularity
CHAPTER 3 R&D APPROACH
- Classification of pipeline products
  - Cytotoxics
  - Antihormonal therapies
  - Molecular targeted therapies
  - Immunotherapeutic agents
- Oncology clinical trial design
CHAPTER 4 BLADDER CANCER
- Overview of bladder cancer
  - Definition
    - Bladder cancer is a common tumor type in males
  - Epidemiology
    - Incidence of bladder cancer will rise due to an increase in industrialization, lifestyle factors and an ageing population
    - Mortality from bladder cancer is very low in the early stages, however, rises dramatically once the tumor spreads
  - Treatment of bladder cancer
- Unmet need in bladder cancer
  - Summary of unmet needs
    - Increase early diagnosis to enhance survival
    - Agents with better routes of administration in comparison with intravesical therapy
    - A better ' standard' for advanced disease with less toxicity is needed
    - Salvation of the bladder is the ideal
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Urocidin (MCC; Bioniche)
    - Drug overview
    - Key historical events
    - Clinical development in bladder cancer
    - Datamonitor comments
  - EOquin (apaziquone; Spectrum Pharmaceuticals)
    - Drug overview
    - Key historical events
    - Clinical development in bladder cancer
    - Datamonitor comments
  - Valstar (valrubicin; Indevus)
    - Drug overview
    - Key historical events
    - Clinical development in bladder cancer
    - Datamonitor comments
  - Larotaxel (XRP-9881; Sanofi-Aventis)
    - Drug overview
    - Key historical events
    - Clinical development in bladder cancer
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Some satisfaction of unmet needs will occur, however, further research is needed in advanced disease
CHAPTER 5 BREAST CANCER
- Overview of breast cancer
  - Definition
    - Breast cancer remains the most common cancer and second most common cause of cancer-related death in women worldwide
  - Epidemiology
    - Incidence of breast cancer will continue to rise as lifestyles associated with risk factors are increasingly adopted and in line with the ageing population
    - While mortality rates are low in comparison to incidence, absolute mortality shows breast cancer remains a leading cause of death in women
  - Treatment of breast cancer
- Unmet need in breast cancer
  - Summary of unmet needs
    - Effective treatment for metastatic disease still remains elusive
    - A wider range of treatment options is necessary for hormone receptor-negative and HER-2 negative patients
    - Elderly patients remain underserved in terms of treatment options
    - More convenient and better tolerated therapies are needed
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Afinitor (everolimus; Novartis)
    - Drug overview
    - Key historical events
    - Clinical development in breast cancer
    - Datamonitor comments
  - Armala (pazopanib; GlaxoSmithKline)
    - Drug overview
    - Key historical events
    - Clinical development in breast cancer
    - Datamonitor comments
  - Omnitarg (pertuzumab; Genentech/Roche/Chugai)
    - Drug overview
    - Key historical events
    - Clinical development in breast cancer
    - Datamonitor comments
  - Sutent (sunitinib; Pfizer)
    - Drug overview
    - Key historical events
    - Clinical development in breast cancer
    - Datamonitor comments
  - Ramucirumab (IMC-1121B; ImClone)
    - Drug overview
    - Key historical events
    - Clinical development in breast cancer
    - Datamonitor comments
  - Eribulin (E7389; Eisai)
    - Drug overview
    - Key historical events
    - Clinical development in breast cancer
    - Datamonitor comments
  - Satisfaction of unmet needs
    - The four targeted therapies in late-phase development for breast cancer show promise in fulfilling some unmet need
CHAPTER 6 CERVICAL CANCER
- Overview of cervical cancer
  - Definition
    - Cervical cancer constitutes 17% of all gynecological tumors
  - Epidemiology
    - Incidence rates of cervical cancer have decreased due to screening programs, however overall incidence will rise in line with the ageing population
    - Mortality is relatively high in comparison to incidence of cervical cancer given its propensity for early diagnosis
  - Treatment of cervical cancer
- Unmet need in cervical cancer
  - Summary of unmet needs
    - Better systemic therapy is required for metastatic and recurrent disease
    - More large-scale, randomized clinical trials are necessary to define optimal treatment strategies across cervical cancer
    - The cervical cancer pipeline is relatively sparse
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Gemzar (gemcitabine; Eli Lilly)
    - Drug overview
    - Key historical events
    - Clinical development in cervical cancer
    - Datamonitor comments
  - Tirazone (tirapazamine; National Cancer Institute/Stanford University/SRI International)
    - Drug overview
    - Key historical events
    - Clinical development in cervical cancer
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Unmet needs are unlikely to be fulfilled by the current pipeline
CHAPTER 7 OVARIAN CANCER
- Overview of ovarian cancer
  - Definition
    - Ovarian cancer is the most frequent cause of cancer-related death from gynecological malignancies
  - Epidemiology
    - Incidence of ovarian cancer will rise in line with the ageing population since it affects primarily postmenopausal women
    - Mortality from ovarian cancer is relatively high in comparison with its incidence due to a high rate of diagnosis at Stage III disease
  - Treatment of ovarian cancer
- Unmet need in ovarian cancer
  - Summary of unmet needs
    - Earlier rates of diagnosis are needed
    - Less invasive surgical techniques are required
    - More effective systemic therapies are needed across multiple lines of treatment
    - Increase level of R&D interest
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Avastin (bevacizumab; Genentech/Roche)
    - Drug overview
    - Key historical events
    - Clinical development in ovarian cancer
    - Datamonitor comments
  - Telcyta (canfosfamide; Telik)
    - Drug overview
    - Key historical events
    - Clinical development in ovarian cancer
    - Datamonitor comments
  - Phenoxodiol (Marshall Edwards)
    - Drug overview
    - Key historical events
    - Clinical development in ovarian cancer
    - Datamonitor comments
  - Karenitecin (cositecan; BioNumerik)
    - Drug overview
    - Key historical events
    - Clinical development in ovarian cancer
    - Datamonitor comments
  - Opaxio (paclitaxel poliglumex; Cell Therapeutics/Novartis)
    - Drug overview
    - Key historical events
    - Clinical development in ovarian cancer
    - Datamonitor comments
  - Yondelis (trabectedin; PharmaMar/Johnson & Johnson)
    - Drug overview
    - Key historical events
    - Clinical development in ovarian cancer
    - Datamonitor comments
  - Patupilone (EPO-906; Novartis)
    - Drug overview
    - Key historical events
    - Clinical development in ovarian cancer
    - Datamonitor comments
  - Abagovomab (ACA-125; Menarini/CellControl BioMedical)
    - Drug overview
    - Key historical events
    - Clinical development in ovarian cancer
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Unmet needs in ovarian cancer will be fulfilled to some extent by means of providing numerous alternative treatment options
CHAPTER 8 PROSTATE CANCER
- Overview of prostate cancer
  - Definition
    - The most common cancer type and second-leading cause of cancer-related death in males
  - Epidemiology
    - Incidence of prostate cancer continues to rise with advances in screening procedures
    - Mortality from prostate cancer is relatively low given the high propensity for early diagnosis
  - Treatment of prostate cancer
- Unmet need in prostate cancer
  - Summary of unmet needs
    - Side effects from antihormonal therapies may affect compliance
    - Alternative treatment options are needed for hormone-refractory patients
    - Greater R&D interest is needed in terms of innovative therapies
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Avastin (bevacizumab; Genentech/Roche)
    - Drug overview
    - Key historical events
    - Clinical development in prostate cancer
    - Datamonitor comments
  - Xinlay (atrasentan; Abbott)
    - Drug overview
    - Key historical events
    - Clinical development in prostate cancer
    - Datamonitor comments
  - Abiraterone (CB-7630; Cougar Biotechnology/BTG)
    - Drug overview
    - Key historical events
    - Clinical development in prostate cancer
    - Datamonitor comments
  - Aflibercept (VEGF-Trap; Regeneron/Sanofi-Aventis)
    - Drug overview
    - Key historical events
    - Clinical development in prostate cancer
    - Datamonitor comments
  - Zibotentan (ZD-4054; AstraZeneca)
    - Drug overview
    - Key historical events
    - Clinical development in prostate cancer
    - Datamonitor comments
  - Cabazitaxel (XRP-6258; Sanofi-Aventis)
    - Drug overview
    - Key historical developments
    - Clinical development in prostate cancer
    - Datamonitor comments
  - Firmagon (degarelix; Ferring/Astellas)
    - Drug overview
    - Key historical developments
    - Clinical development in prostate cancer
    - Datamonitor comments
  - GVAX (CG-8123; Cell Genesys/Takeda)
    - Drug overview
    - Key historical events
    - Clinical development in prostate cancer
    - Datamonitor comments
  - Provenge (sipuleucel-T; Dendreon)
    - Drug overview
    - Key historical events
    - Clinical development in prostate cancer
    - Datamonitor comments
  - Tookad (padoporfin; Weizmann Institute/Steba Biotech)
    - Drug overview
    - Key historical events
    - Clinical development in prostate cancer
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Superiority over current standard therapies is unlikely to be shown by the current pipeline
CHAPTER 9 RENAL CELL CARCINOMA
- Overview of renal cell carcinoma
  - Definition
    - Renal cell carcinoma has become a popular R&D indication for drug developers
  - Epidemiology
    - Incidence of renal cell carcinoma will continue to rise in line with the ageing population, increasing rates of obesity and more frequent diagnosis following imaging procedures
    - Mortality is high in late-stage RCC patients
  - Treatment of RCC
- Unmet need in RCC
  - Summary of unmet need
    - Adjuvant therapy to prevent relapse following surgery in Stage I-III patients
    - More systemic therapies required to provide options in later lines of treatment
    - Non-clear cell RCC subtypes must be the focus of future therapies
- Pipeline overview
  - Pipeline summary
  - Late-phase pipeline
  - Phase II pipeline
  - Comparative forecasts
  - Definition of current comparator therapy
- Pipeline candidates
  - Afinitor (everolimus; Novartis)
    - Drug overview
    - Key historical events
    - Clinical development in RCC
    - Datamonitor comments
  - Armala (pazopanib; GlaxoSmithKline)
    - Drug overview
    - Key historical events
    - Clinical development in RCC
    - Datamonitor comments
  - Rencarex (WX-G250; Wilex)
    - Drug overview
    - Key historical events
    - Clinical development in RCC
    - Datamonitor comments
  - Axitinib (AG-13736; Pfizer)
    - Drug overview
    - Key historical events
    - Clinical development in RCC
    - Datamonitor comments
  - Oncophage (vitespen; Antigenics)
    - Drug overview
    - Key historical events
    - Clinical development in RCC
    - Datamonitor comments
  - Reniale (LipoNova)
    - Drug overview
    - Key historical events
    - Clinical development in RCC
    - Datamonitor comments
  - TroVax (MVA-h5T4; Oxford Biomedica/Sanofi-Aventis)
    - Drug overview
    - Key historical events
    - Clinical development in RCC
    - Datamonitor comments
  - Satisfaction of unmet needs
    - Afinitor shows great promise for fulfilling unmet needs in later lines of therapy, while Rencarex and Reniale show potential in the adjuvant setting
APPENDIX A
- Bibliography
- List of tables
- List of figures
- List of abbreviations
- Contributing experts
- Methodology
  - Datamonitor forecast methodology
    - Epidemiology forecasts
    - Product forecasts
  - Datamonitor drug assessment summary
APPENDIX B
- About Datamonitor
  - About Datamonitor Healthcare
- Datamonitor Healthcare' s therapy area capabilities
  - About the Disease analysis team
  - Disclaimer
List of Tables
- Table 1: Late-phase cytotoxics pipeline for bladder cancer, breast cancer, cervical cancer, ovarian cancer, prostate cancer and RCC, 2008
- Table 2: Late-phase immunotherapies pipeline for bladder cancer, breast cancer, cervical cancer, ovarian cancer, prostate cancer and RCC, 2008
- Table 3: Late-phase endocrine and photodynamic therapies pipeline for bladder cancer, breast cancer, cervical cancer, ovarian cancer, prostate cancer and RCC, 2008
- Table 4: Late-phase targeted therapies pipeline for bladder cancer, breast cancer, cervical cancer, ovarian cancer, prostate cancer and RCC, 2008
- Table 5: Pipeline split by developmental phase and indication, 2008
- Table 6: Cytotoxic subgroup mechanisms of action
- Table 7: Antihormonal subgroup mechanisms of action
- Table 8: Targeted therapy subgroup mechanisms of action
- Table 9: Immunotherapy subgroup mechanisms of action
- Table 10: Oncology clinical trial design factors
- Table 11: Crude incidence rate of bladder cancer per 100,000 population in the seven major pharmaceutical markets, 2002
- Table 12: Forecast incidence of bladder cancer in the seven major pharmaceutical markets, 2002-2017
- Table 13: Five-year survival rates by stage of bladder cancer, 1975-2000
- Table 14: Late-phase bladder cancer pipeline, 2008
- Table 15: Phase II bladder cancer pipeline, 2008
- Table 16: Forecasting assumptions for bladder cancer pipeline products across the seven major markets, 2008 (1 of 2)
- Table 17: Forecasting assumptions for bladder cancer pipeline products across the seven major markets, 2008 (2 of 2)
- Table 18: Pipeline bladder cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Table 19: TheraCys: key historical facts
- Table 20: Urocidin: key historical events
- Table 21: Clinical development of Urocidin in bladder cancer, 2008
- Table 22: EOquin: key historical events
- Table 23: Clinical development of EOquin in bladder cancer, 2008
- Table 24: Valstar: key historical events
- Table 25: Larotaxel: key historical events
- Table 26: Clinical development of larotaxel in bladder cancer, 2008
- Table 27: Fulfillment of unmet needs by pipeline bladder cancer drugs, 2008
- Table 28: Forecast incidence of breast cancer in the seven major pharmaceutical markets, 2002-2017
- Table 29: Eight-year survival rates by stage of breast cancer
- Table 30: Phase III breast cancer pipeline, 2008
- Table 31: Phase II breast cancer pipeline, 2008 (targeted therapies)
- Table 32: Phase II breast cancer pipeline, 2008 (cytotoxics)
- Table 33: Phase II breast cancer pipeline, 2008 (immunotherapies)
- Table 34: Phase II breast cancer pipeline, 2008 (miscellaneous)
- Table 35: Forecasting assumptions for breast cancer pipeline products across the seven major markets, 2008 (1 of 2)
- Table 36: Forecasting assumptions for breast cancer pipeline products across the seven major markets, 2008 (2 of 2)
- Table 37: Pipeline breast cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Table 38: Taxotere: key historical facts
- Table 39: Afinitor: key historical events
- Table 40: Clinical development of Afinitor in breast cancer, 2008
- Table 41: Armala: key historical events
- Table 42: Clinical development of Armala in breast cancer, 2008
- Table 43: Omnitarg: key historical events
- Table 44: Clinical development of Omnitarg in breast cancer, 2008
- Table 45: Sutent: key historical events
- Table 46: Clinical development of Sutent in breast cancer, 2008
- Table 47: Ramucirumab: key historical events
- Table 48: Clinical development of ramucirumab in breast cancer, 2008
- Table 49: Eribulin: key historical events
- Table 50: Clinical development of eribulin in breast cancer, 2008
- Table 51: Fulfillment of unmet needs by pipeline breast cancer drugs, 2008
- Table 52: Datamonitor' s forecast incidence of cervical cancer in the seven major pharmaceutical markets, 2002-2017
- Table 53: Phase III cervical cancer pipeline, 2008
- Table 54: Phase II cervical cancer pipeline, 2008 (targeted therapies)
- Table 55: Phase II cervical cancer pipeline, 2008 (cytotoxics and immunotherapies)
- Table 56: Forecasting assumptions for pipeline cervical cancer products across the seven major markets, 2008
- Table 57: Pipeline cervical cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Table 58: Hycamtin: key historical facts
- Table 59: Gemzar: key historical events
- Table 60: Clinical development of Gemzar in cervical cancer, 2008
- Table 61: Phase II study results investigating single-agent Gemzar in previously treated advanced cervical cancer
- Table 62: Phase II study results investigating second-line Gemzar-based combination regimens in advanced cervical cancer
- Table 63: Tirazone: key historical events
- Table 64: Clinical development of Tirazone in cervical cancer, 2008
- Table 65: Fulfillment of unmet needs by pipeline cervical cancer drugs, 2008
- Table 66: Datamonitor' s forecast incidence of ovarian cancer in the seven major pharmaceutical markets, 2002-2017
- Table 67: Stage distribution at diagnosis
- Table 68: Five-year survival rate by stage of ovarian cancer
- Table 69: Phase III ovarian cancer pipeline, 2008
- Table 70: Phase II ovarian cancer pipeline, 2008 (targeted therapies)
- Table 71: Phase II ovarian cancer pipeline, 2008 (cytotoxics)
- Table 72: Phase II ovarian cancer pipeline, 2008 (miscellaneous)
- Table 73: Forecasting assumptions for pipeline ovarian cancer products across the seven major markets, 2008 (1 of 3)
- Table 74: Forecasting assumptions for pipeline ovarian cancer products across the seven major markets, 2008 (2 of 3)
- Table 75: Forecasting assumptions for pipeline ovarian cancer products across the seven major markets, 2008 (3 of 3)
- Table 76: Pipeline ovarian cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Table 77: Hycamtin: key historical facts
- Table 78: Avastin: key historical events
- Table 79: Clinical development of Avastin in ovarian cancer, 2008
- Table 80: Telcyta: key historical events
- Table 81: Clinical development of Telcyta in ovarian cancer, 2008
- Table 82: Phenoxodiol: key historical events
- Table 83: Clinical development of phenoxodiol in ovarian cancer, 2008
- Table 84: Karenitecin: key historical events
- Table 85: Clinical development of Karenitecin in ovarian cancer, 2008
- Table 86: Opaxio: key historical events
- Table 87: Clinical development of Opaxio in ovarian cancer, 2008
- Table 88: Yondelis: key historical events
- Table 89: Clinical development of Yondelis in ovarian cancer, 2008
- Table 90: Patupilone: key historical events
- Table 91: Clinical development of patupilone in ovarian cancer, 2008
- Table 92: Abagovomab: key historical events
- Table 93: Clinical development of abagovomab in ovarian cancer, 2008
- Table 94: Fulfillment of unmet needs by pipeline ovarian cancer drugs, 2008
- Table 95: Datamonitor' s forecast incidence of prostate cancer in the seven major pharmaceutical markets, 2002-2017
- Table 96: Late-phase prostate cancer pipeline, 2008
- Table 97: Phase II prostate cancer pipeline, 2008 (targeted therapies)
- Table 98: Phase II prostate cancer pipeline, 2008 (cytotoxics)
- Table 99: Phase II prostate cancer pipeline, 2008 (immunotherapies)
- Table 100: Phase II prostate cancer pipeline, 2008 (miscellaneous)
- Table 101: Forecasting assumptions for pipeline prostate cancer products across the seven major markets, 2008 (1 of 3)
- Table 102: Forecasting assumptions for pipeline prostate cancer products across the seven major markets, 2008 (2 of 3)
- Table 103: Forecasting assumptions for pipeline prostate cancer products across the seven major markets, 2008 (3 of 3)
- Table 104: Pipeline prostate cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Table 105: Taxotere: key historical facts
- Table 106: Avastin: key historical events
- Table 107: Clinical development of Avastin in prostate cancer, 2008
- Table 108: Xinlay: key historical events
- Table 109: Clinical development of Xinlay in prostate cancer, 2008
- Table 110: Abiraterone: key historical events
- Table 111: Clinical development of abiraterone in prostate cancer, 2008
- Table 112: Aflibercept: key historical events
- Table 113: Clinical development of aflibercept in prostate cancer, 2008
- Table 114: Zibotentan: key historical events
- Table 115: Clinical development of zibotentan in prostate cancer, 2008
- Table 116: Cabazitaxel: key historical events
- Table 117: Clinical development of cabazitaxel in prostate cancer, 2008
- Table 118: Firmagon: key historical events
- Table 119: Clinical development of Firmagon in prostate cancer, 2008
- Table 120: GVAX: key historical events
- Table 121: Clinical development of GVAX in prostate cancer, 2008
- Table 122: Phase II results for GVAX monotherapy in HRPC
- Table 123: Provenge: key historical events
- Table 124: Clinical development of Provenge in prostate cancer, 2008
- Table 125: Tookad: key historical events
- Table 126: Clinical development of Provenge in prostate cancer, 2008
- Table 127: Fulfillment of unmet needs by pipeline prostate cancer drugs, 2008
- Table 128: Datamonitor' s forecast incidence of RCC in the seven major pharmaceutical markets, 2002-2017
- Table 129: Five-year survival rate by stage of RCC, 2004
- Table 130: Stage of RCC at diagnosis
- Table 131: Phase III RCC pipeline, 2008
- Table 132: Phase II RCC pipeline, 2008 (targeted therapies)
- Table 133: Phase II RCC pipeline, 2008 (immunotherapies)
- Table 134: Phase II RCC pipeline, 2008 (cytotoxics)
- Table 135: Forecasting assumptions for pipeline RCC products across the seven major markets, 2008 (1 of 2)
- Table 136: Forecasting assumptions for pipeline RCC products across the seven major markets, 2008 (2 of 2)
- Table 137: Pipeline RCC product sales forecasts across the seven major markets, 2008-2017 ($m)
- Table 138: Sutent: key facts
- Table 139: Afinitor: key historical events
- Table 140: Clinical development of Afinitor in RCC, 2008
- Table 141: Armala: key historical events
- Table 142: Clinical development of Armala in RCC, 2008
- Table 143: Rencarex: key historical events
- Table 144: Clinical development of Rencarex in RCC, 2008
- Table 145: Axitinib: key historical events
- Table 146: Clinical development of axitinib in RCC, 2008
- Table 147: Oncophage: key historical events
- Table 148: Reniale: key historical events
- Table 149: TroVax: key historical events
- Table 150: Clinical development of TroVax in RCC, 2008
- Table 151: Fulfillment of unmet needs by pipeline RCC drugs, 2008
- Table 152: List of abbreviations
- Table 153: Datamonitor drug assessment parameters
List of Figures
- Figure 1: Forecast incidence and mortality from bladder cancer in 2008 and 2017 across the seven major markets
- Figure 2: Summary of unmet needs in the bladder cancer market, 2008
- Figure 3: Datamonitor drug assessment summary for the pipeline bladder cancer products, 2008
- Figure 4: Pipeline bladder cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Figure 5: Phase II study investigating Urocidin in high-risk superficial bladder cancer
- Figure 6: Phase II study investigating EOquin in recurrent non-invasive bladder cancer
- Figure 7: Forecast incidence and mortality from breast cancer in 2008 and 2017 across the seven major markets
- Figure 8: Summary of unmet needs in the breast cancer market, 2008
- Figure 9: Datamonitor drug assessment summary for the pipeline breast cancer products, 2008
- Figure 10: Pipeline breast cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Figure 11: Phase II trial results investigating neoadjuvant Afinitor plus Femara in hormone receptor-positive breast cancer
- Figure 12: Phase II results investigating first/second-line Afinitor monotherapy in metastatic breast cancer
- Figure 13: Phase II results investigating first-line Tykerb with or without Armala in HER-2-positive advanced or metastatic breast cancer
- Figure 14: Phase II results investigating Omnitarg plus Herceptin in HER-2-positive metastatic breast cancer following failure of prior Herceptin
- Figure 15: Phase II results investigating single-agent Omnitarg metastatic breast cancer with low HER-2 expression
- Figure 16: Phase II results investigating single-agent Sutent in previously treated metastatic breast cancer
- patients
- Figure 18: Phase II study investigating third-line or higher eribulin in chemotherapy-refractory advanced breast cancer patients
- Figure 19: Incidence and mortality from cervical cancer in 2008 and 2017 across the seven major markets
- Figure 20: Summary of unmet needs in the cervical cancer market, 2008
- Figure 21: Datamonitor drug assessment summary for the pipeline cervical cancer products, 2008
- Figure 22: Pipeline cervical cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Figure 23: Phase II trial investigating first/second-line Tirazone and cisplatin in metastatic cervical cancer patients (Maluf study)
- Figure 24: Phase II trial investigating first-line Tirazone and cisplatin in metastatic cervical cancer patients
- Figure 25: Incidence and mortality from ovarian cancer in 2008 and 2017 across the seven major markets
- Figure 26: Summary of unmet needs in the ovarian cancer market, 2008
- Figure 27: Datamonitor drug assessment summary for the pipeline ovarian cancer products, 2008
- Figure 28: Pipeline ovarian cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Figure 29: Phase II trial investigating Avastin monotherapy or combination chemotherapy regimens in heavily pretreated ovarian cancer
- Figure 30: Phase II trial investigating third-line Avastin and Hycamtin in platinum-refractory recurrent ovarian cancer
- Figure 31: Phase II trial investigating first-line Avastin, cisplatin and paclitaxel in optimally debulked Stage II/III ovarian cancer
- Figure 32: Phase III ASSIST-1 study comparing third-line Telcyta with Doxil or Hycamtin
- Figure 33: Phase III ASSIST-3 study comparing second-line Telcyta + carboplatin with Doxil
- Figure 34: Preliminary Phase IIa results investigating a second-line combination of phenoxodiol with either paclitaxel or cisplatin
Figure 35: Phase II results investigating third-line Karenitecin in recurrent or persistent ovarian cancer
- Figure 36: Phase II trial results investigating Opaxio in newly diagnosed Stage III/IV ovarian cancer patients
- Figure 37: Pooled results from three Phase II trials investigating Yondelis in advanced relapsed ovarian cancer
- Figure 38: Phase I/II trial investigating second-line patupilone in refractory or relapsed advanced ovarian cancer
- Figure 39: Phase I/II trial investigating maintenance abagovomab following chemotherapy for recurrent ovarian cancer
- Figure 40: Incidence and mortality from prostate cancer in 2008 and 2017 across the seven major markets
- Figure 41: Summary of unmet needs in the prostate cancer market, 2008
- Figure 42: Datamonitor drug assessment summary for the pipeline prostate cancer products, 2008
- Figure 43: Pipeline prostate cancer product sales forecasts across the seven major markets, 2008-2017 ($m)
- Figure 44: Initial Phase II results investigating first-line Avastin, Taxotere and estramustine in metastatic HRPC
- Figure 45: Phase II results investigating first-line Avastin, Taxotere and Thalomid in metastatic HRPC
- Figure 46: Meta-analysis of pooled data from the M96-594 and M00-211 clinical trials in metastatic HRPC
- Figure 47: Phase III M00-244 study results in non-metastatic HRPC
- Figure 48: Preliminary Phase II COU-AA-004 results for second/third-line abiraterone and prednisone in advanced HRPC
- Figure 49: Combined COU-AA-001 Phase I/II and COU-AA-003 Phase II results in chemotherapy-naïve patients and taxane-pretreated patients
- Figure 50: Phase II study investigating first-line zibotentan in HRPC metastatic to the bone
- Figure 51: Phase III CS21 study results comparing Firmagon to Lupron in hormone-sensitive prostate cancer
- Figure 52: Phase III D9901 results investigating Provenge in asymptomatic metastatic HRPC
- Figure 53: Analysis of patient subgroup from Phase III D9901 and D9902A studies who received Taxotere following Provenge or placebo
- Figure 54: Phase III PROTECT results investigating Provenge in hormone-sensitive non-metastatic prostate cancer
- Figure 55: Incidence and mortality from RCC in 2008 and 2017 across the seven major markets
- Figure 56: Summary of unmet needs in the RCC market, 2008
- Figure 57: Datamonitor drug assessment summary for the pipeline RCC cancer products, 2008
- Figure 58: Pipeline RCC product sales forecasts across the seven major markets, 2008-2017 ($m)
- Figure 59: Phase III RECORD-1 trial results investigating Afinitor in tyrosine kinase inhibitor-refractory metastatic RCC
- Figure 60: Final analysis of a Phase II trial investigating single-agent Armala in cytokine-naïve and refractory patients
- Figure 61: Phase II results for Rencarex monotherapy in metastatic RCC
- Figure 62: Phase II results for Rencarex and interferon-alfa in metastatic RCC
- Figure 63: Phase II results for axitinib in RCC patients refractory to Sutent, Nexavar and/or cytokine therapy
- Figure 64: Phase III trial data investigating adjuvant Reniale
- Figure 65: Datamonitor drug assessment summary of pipeline molecular targeted therapies in development for hematological malignancies, 2007

簡介
目錄
相關商品

使用指南產品及服務須知網站導覽

星期一到星期五 / 9:30am - 6:00pm
TEL: 02-2729-4219 (+886-2-2729-4219)
E-mail: tw-info@gii.co.jp

癌症概要：乳癌、婦科癌症、泌尿生殖器癌症

Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor types